Unfortunately, shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have suffered share price declines over the last year. To wit the share price is down 54% in that time. To make matters worse, ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

CAMBRIDGE, Mass. - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a $5.3 billion biotechnology company with strong financial health indicators and over 50% revenue growth in the past year, has received ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Neurocrine (NBIX – Research Report), with a ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Argenx Se (ARGX – Research Report), with a ...

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price ...